Parkinson Disease

In assessing symptoms of Parkinson disease exacerbated by the coronavirus disease 2019 (COVID-19) pandemic, nonmotor neuropsychiatric and automatic symptoms were noted to particularly affect both patients and their respective caregivers.

Researchers examine the clinical and pathophysiological mechanisms underlying pain in Parkinson disease.

Spinal cord stimulation was found to decrease pain and reduce motor symptoms of Parkinson disease as both a singular therapy and as a salvage therapy after deep brain stimulation therapies proved ineffective.

Researchers assess the optimal balance of levodopa in patients with Parkinson disease (PD), which wanes in efficacy as PD progresses and can contribute to uncontrollable, involuntary bodily movements if given in too high of a dosage.

Amid the COVID-19 pandemic, health professionals reported difficulty accessing Parkinson disease medications, particularly in low-income countries, leading to greater disability of patients as a result.

Researchers present a novel approach to identifying molecules associated with the progression of Parkinson disease and other neurodegenerative diseases.

People with Parkinson disease (PD) were found to be more likely than those without the condition to have orthostatic hypotension, a sudden drop in blood pressure upon standing that can exacerbate the risk of falling.

A review discusses what immunotherapies are currently being evaluated to target α-synuclein, an abnormal protein suggested to have a central role in the pathogenesis of PD.

Exercise was identified as a potential intervention to improve quality of life and heighten immune response among patients with Parkinson disease.

Among patients with advanced Parkinson disease and motor fluctuations, a combination of levodopa/carbidopa/entacapone was shown to improve motor and sleep symptoms.

A healthy diet consisting of fruit, vegetables, and whole grains in middle age may be associated with fewer non-motor symptoms known to precede the diagnosis of Parkinson disease, according to study findings.

There was no statistically significant difference in patient-reported outcomes for short-term integrated palliative care compared with standard care in those with long-term neurological conditions.

Researchers explore the standard pathophysiological and molecular linkages between Parkinson disease (PD) and diabetes, as well as the role of diabetes therapies in the pathological pathways and progression of PD.

Among patients with Parkinson disease (PD), co-occurrence of dementia and hypertension, as well as duration of PD, were significantly associated with mortality due to coronavirus disease 2019 (COVID-19), according to a recent study.

Researchers find that monitoring dietary intake in patients with Parkinson disease (PD) could detect possible micronutrient insufficiencies that may exacerbate adverse effects such as constipation. Expanding knowledge on correct medication intake among patients with PD was also cited.

Switching off a “master regulator” of the epigenome called TET2 may protect the brain from the inflammatory damage and neurodegeneration caused by Parkinson disease, according to recent study findings.

DA-9701 therapy was found to improve the severity of gastrointestinal symptom–related quality of life and severity in patients with Parkinson disease, with no adverse effects on motor symptoms, according to study findings.

Among patients with Parkinson disease aged 60 years and younger with early motor complications, deep brain stimulation was found to provide significant improvements in social, occupational, and psychosocial function.

Improving on the ability to confirm diagnosis of Parkinson disease (PD) earlier and determining who is at risk for PD were referenced as key factors in further slowing progression of the disease, according to review findings.

Overall, there are 145 registered and ongoing clinical trials for therapies targeting Parkinson disease, of which 28 are currently in phase 3, according to review findings.

Researchers discuss the implications of nonmotor symptoms in patients with Parkinson disease, which can contribute to major sleep, ocular, olfactory, throat, cardiovascular, gastrointestinal, genitourinary, or musculoskeletal disorders.

Individuals who had experienced a concussion were found to be at a greater risk of Parkinson disease, mood and anxiety disorders (MADs), dementia, and hyperactivity disorder, with concussed women indicated as a notable at-risk population for MADs, according to study findings published today.

A recent webinar discussed what causes symptom recurrence in patients with Parkinson disease and what implications this has for health outcomes and health care cost.

Patients with Parkinson disease who experience visual impairment were found to be more prone to behavioral issues such as depression and anxiety, as well as dementia and death, according to study findings.

A quality improvement project led by a multidisciplinary team was found to significantly improve on-time administration of levodopa and other medications for patients with Parkinson disease, according to study findings.

In patients with Parkinson disease (PD) who underwent deep brain stimulation, dementia prevalence and incidence were not found to be higher than those in the general PD population, according to study findings.

Seven symptoms were identified as most predictive of early morning OFF periods (EMO) in patients with Parkinson disease, which may assist in understanding and managing potential determinants and negative health effects of EMO.

Health-related quality of life and caregiver burden were both significantly correlated with alexithymia in patients with Parkinson disease, with the sub-component “identifying feelings” serving as a key factor.